According to expression pattern of BCAT2 in scRNA level, specifically expressed in tumor cells rather than in immune cells and endothelial cells, we can preliminarily infer that BCAT2 loss or inhibitor of BCAT2 less likely results in terrible adverse effects. Here, BCAT2 is linked to neoplasm.